Eric D. Achtyes

Eric D. Achtyes

Auto-generated profile, based on publicly available information

Eric D. Achtyes

Department of Psychiatry, Western Michigan University Homer Stryker M.D. School of Medicine

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
YFYen-Chen Anne Feng
Yen-Chen Anne Feng
DHDaniel P. Howrigan
Daniel P. Howrigan
LALiam E. Abbott
Liam E. Abbott
KTKatherine Tashman
Katherine Tashman
FCFelecia Cerrato
Felecia Cerrato
BNBenjamin M. Neale
Benjamin M. Neale

8 January 2014 in JAMA
Verified
Journal Article
Open access
PDF file
AEA. Eden Evins
A. Eden Evins
CCCorinne Cather
Corinne Cather
SPSarah A. Pratt
Sarah A. Pratt
GPGladys N. Pachas
Gladys N. Pachas
SHSusanne S. Hoeppner
Susanne S. Hoeppner
DSDavid A. Schoenfeld
David A. Schoenfeld
Although tobacco smoking among adults has declined by 55% in the United States since 1965,1 smoking prevalence among adults with serious mental illness remains higher now than it was in the general population in 1965.2 Six million of the 11.4 million adults (53%) with serious mental illness smoke tobacco.3 Relatively small trials have reported pharmacologic cessation aids—including bupropion alone or combined with nicotine replacement therapy and varenicline—increase initial abstinence rates over behavioral treatment alone for smokers with schizophrenia and schizoaffective disorder, with mean abstinence rates of 24% at the end of 8 to 12 weeks of treatment vs 5% with placebo plus behavioral therapy, suggesting behavioral treatment alone is ineffective for smoking cessation in this population.4-11 Abstinence rates in pharmacotherapy treatment groups declined from 24% to 12% 3 months after discontinuing pharmacotherapy,12 with some trials reporting the majority of relapses occurring within 2 weeks of stopping the medication,8 suggesting a possible need for longer-term pharmacotherapy for prolonged tobacco abstinence in this population.

1 December 2020 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
JKJohn M. Kane
John M. Kane
NSNina R. Schooler
Nina R. Schooler
PMPatricia Marcy
Patricia Marcy
CCChristoph U. Correll
Christoph U. Correll
EAEric D. Achtyes
Eric D. Achtyes
DRDelbert G. Robinson
Delbert G. Robinson
The prevention of relapse and hospitalization in schizophrenia is a major public health challenge. Antipsychotic medications reduce the relapse risk compared with placebo with a number to treat (NNT) of 3,1 and epidemiological studies find substantial reductions in all-cause mortality compared with no use.2 Long-acting injectable antipsychotics (LAIs) are superior to oral counterparts in this regard.3-5

8 August 2015 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Open access
PDF file
LBL. Brundin
L. Brundin
SES. Erhardt
S. Erhardt
EBE. Y. Bryleva
E. Y. Bryleva
EAE. D. Achtyes
E. D. Achtyes
Teodor T. PostolacheTeodor T. Postolache
Teodor T. Postolache
Objective: Over the past decade, clinical data have accumulated showing that inflammation might contribute to the pathophysiology of suicide. To evaluate the associations and to identify the support for pathways linking inflammatory processes with suicidal behaviour, a comprehensive review of the literature was undertaken.Method: The search terms ‘cytokine’, ‘risk factors’, ‘kynurenine’, ‘asthma’, ‘allergy’, ‘autoimmunity’, ‘traumatic brain injury’, ‘infection’ along with the terms ‘inflammation’ and ‘suicide’ were entered intoPubMed, and a thorough analysis of the publications and their reference lists was performed.Results: The effects of inflammation on mood and behaviour could partially be mediated by kynurenine pathway metabolites, modulating neuroinflammation and glutamate neurotransmission. At the same time, the triggers of the inflammatory changes documented in suicidal patients may be attributed to diverse mechanisms such as autoimmunity, neurotropic pathogens, stress or traumatic brain injury.Conclusion: Targeting the inflammatory system might provide novel therapeutic approaches as well as potential biomarkers to identify patients at increased risk. For the goal of improved detection and treatment of suicidal individuals to be achieved, we need to develop a detailed understanding of the origin, mechanisms and outcomes of inflammation in suicidal behaviour.

1 January 2020 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
EAEric Achtyes
Eric Achtyes
SKSarah A. Keaton
Sarah A. Keaton
LSLeAnn Smart
LeAnn Smart
ABAmanda R. Burmeister
Amanda R. Burmeister
PHPatrick L. Heilman
Patrick L. Heilman
LBLena Brundin
Lena Brundin

1 May 2013 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
JRJoshua L. Roffman
Joshua L. Roffman
JLJ. Steven Lamberti
J. Steven Lamberti
EAEric Achtyes
Eric Achtyes
EMEric A. Macklin
Eric A. Macklin
GGGail C. Galendez
Gail C. Galendez
DGDonald C. Goff
Donald C. Goff
Schizophrenia is a chronic psychiatric illness characterized by positive symptoms (delusions, hallucinations, and disorganization), negative symptoms (apathy, social withdrawal, and loss of emotional expressiveness), and cognitive impairment. Antipsychotic medications control positive symptoms sufficiently to allow most individuals to live safely within the community. However, considerable disability is associated with negative symptoms and cognitive deficits, for which effective treatment is not available.1